Bioneer Stock Forecast for 2023 - 2025 - 2030
Updated on 04/20/2024
Bioneer Fair Value Forecast for 2023 - 2025 - 2030
In the last year, Bioneer's Price has decreased by 100.00%, going from ₩36.09k to ₩0.00. For the next year, analysts are expecting Fair Value to reach ₩0.00 – an increase of 100.00%. Over the next six years, experts predict that Fair Value will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A096530 Stock Forecast | Seegene | Outperform |
18
|
₩21.45k | Buy/Sell | ₩25.00k | 16.55% |
| A205470 Stock Forecast | Humasis | - |
14
|
₩1.86k | Buy/Sell | ₩0.00 | -100.00% |
| A228760 Stock Forecast | Genomictree | - |
4
|
₩23.15k | Buy/Sell | ₩24.00k | -100.00% |
| A241820 Stock Forecast | PCL | - |
8
|
₩1.07k | Buy/Sell | ₩0.00 | -100.00% |
| A206640 Stock Forecast | Boditech Med | Outperform |
15
|
₩14.81k | Buy/Sell | ₩20.00k | 75.56% |
Bioneer Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Bioneer's Revenue has grown by 5.51%, from ₩206.99B to ₩218.39B. 0 analysts predict Bioneer's Revenue will decrease by 0.86% in the next year, reaching ₩216.51B. By 2030, professionals predict that Bioneer's Revenue will decrease by 0.81%, to ₩216.63B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A217330 Stock Forecast | Cytogen | - |
7
|
₩14.71k | Buy/Sell | ₩0.00 | -100.00% |
| A220100 Stock Forecast | FutureChem Co.,Ltd | - |
6
|
₩8.35k | Buy/Sell | ₩0.00 | -100.00% |
| A109820 Stock Forecast | GeneMatrix | - |
0
|
₩2.68k | Buy/Sell | ₩0.00 | -100.00% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A038070 Stock Forecast | Seoulin Bioscience | - |
16
|
₩9.48k | Buy/Sell | ₩0.00 | -100.00% |
| A046210 Stock Forecast | HLB PANAGENE Co., LTD. | - |
0
|
₩4.45k | Buy/Sell | ₩0.00 | -100.00% |
| A142280 Stock Forecast | Green Cross Medical Science | - |
9
|
₩4.00k | Buy/Sell | ₩17.00k | -100.00% |
Bioneer EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Bioneer's EBITDA has decreased from ₩110.60B to ₩18.81B – a 82.99% drop! For next year, analysts predict EBITDA of ₩48.39B, which would mean an increase of 157.19%. Over the next eight years, experts predict that Bioneer's EBITDA will grow at a rate of 319.01%.
Bioneer EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Bioneer has seen a decline in its EBIT, from ₩105.22B to ₩10.74B – a 89.79% decrease. In the next year, analysts believe that EBIT will reach ₩39.38B – an increase of 266.56%. For the next eight years, the forecast is for EBIT to grow by 843.17%.
Bioneer EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last year, Bioneer's EPS has decreased by 100.00%, going from ₩2406.00 to ₩0.00. For the next year, analysts are expecting EPS to reach ₩0.00 – an increase of 100.00%. Over the next six years, experts predict that EPS will grow by 100.00%.
.jpg)